

Experiment Number: 03039 - 02
Test Type: CHRONIC
Route: Dermal
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan
CAS Number: 3380-34-5

Date Report Requested: 12/04/2020
Time Report Requested: 13:42:33
First Dose M/F: 09/11/13 / 09/11/13
Lab: NCTR

NTP Study Number: C03039B
Lock Date: 12/18/2017
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.3_002
PWG Approval Date: 10/13/2017

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
------------------	--------------	--------------	--------------	--------------	--------------	--------------

Disposition Summary

Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Accidentally Killed	1					
Moribund	10	18	11	14	18	16
Natural Death	1		2	3	1	
Survivors						
Moribund	1		1		1	1
Terminal Sacrifice	35	30	34	31	28	31
Animals Examined Microscopically	48	48	48	48	48	48

ALIMENTARY SYSTEM

Esophagus	(48)	(48)	(48)	(48)	(48)	(48)
Inflammation, Chronic Active						1 (2%)
Epithelium, Hyperplasia						1 (2%)
Gallbladder	(45)	(44)	(43)	(41)	(40)	(46)
Infiltration Cellular, Lymphocyte				1 (2%)		
Lumen, Dilatation						1 (2%)
Intestine Large, Cecum	(47)	(48)	(46)	(46)	(47)	(48)
Epithelium, Hyperplasia		1 (2%)				
Lymphoid Tissue, Hyperplasia	1 (2%)			1 (2%)	2 (4%)	
Intestine Large, Colon	(48)	(48)	(46)	(46)	(48)	(48)
Fibrosis				1 (2%)		
Inflammation, Suppurative					1 (2%)	
Inflammation, Chronic Active	1 (2%)			2 (4%)		
Necrosis					1 (2%)	
Ulcer					1 (2%)	
Intestine Large, Rectum	(47)	(48)	(46)	(46)	(48)	(48)
Intestine Small, Duodenum	(47)	(48)	(46)	(46)	(47)	(48)
Inflammation, Chronic Active		1 (2%)				
Intestine Small, Ileum	(47)	(48)	(46)	(46)	(47)	(48)
Infiltration Cellular, Histiocyte	1 (2%)					
Lymphoid Tissue, Hyperplasia		1 (2%)			1 (2%)	3 (6%)
Intestine Small, Jejunum	(47)	(48)	(46)	(46)	(47)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Cyst	1 (2%)					
Diverticulum	1 (2%)					
Lymphoid Tissue, Hyperplasia		1 (2%)	1 (2%)		1 (2%)	
Liver	(48)	(48)	(48)	(48)	(48)	(48)
Angiectasis			1 (2%)			
Basophilic Focus	10 (21%)	11 (23%)	8 (17%)	6 (13%)	13 (27%)	9 (19%)
Clear Cell Focus	5 (10%)	6 (13%)	8 (17%)	9 (19%)	6 (13%)	5 (10%)
Congestion					1 (2%)	
Cyst						2 (4%)
Deformity	1 (2%)		2 (4%)		1 (2%)	1 (2%)
Eosinophilic Focus	3 (6%)	1 (2%)		1 (2%)	1 (2%)	1 (2%)
Fatty Change	2 (4%)	2 (4%)				1 (2%)
Fibrosis	1 (2%)	1 (2%)	1 (2%)	1 (2%)	2 (4%)	
Hematopoietic Cell Proliferation		1 (2%)		1 (2%)		
Hemorrhage		1 (2%)			1 (2%)	
Hepatodiaphragmatic Nodule	1 (2%)		2 (4%)			1 (2%)
Infiltration Cellular, Lymphocyte	1 (2%)	1 (2%)	2 (4%)	2 (4%)		1 (2%)
Infiltration Cellular, Polymorphonuclear	1 (2%)			1 (2%)		1 (2%)
Inflammation, Granulomatous	1 (2%)					
Inflammation, Chronic		2 (4%)	1 (2%)		4 (8%)	1 (2%)
Inflammation, Chronic Active	2 (4%)	6 (13%)	2 (4%)	5 (10%)	3 (6%)	2 (4%)
Mineralization					1 (2%)	
Mixed Cell Focus		3 (6%)	1 (2%)	2 (4%)		1 (2%)
Pigmentation	2 (4%)				1 (2%)	
Tension Lipidosis		1 (2%)	1 (2%)			2 (4%)
Thrombosis				4 (8%)		1 (2%)
Vacuolization Cytoplasmic	2 (4%)	1 (2%)	5 (10%)	4 (8%)	3 (6%)	2 (4%)
Bile Duct, Crystals						1 (2%)
Bile Duct, Cyst			1 (2%)			
Bile Duct, Hyperplasia	1 (2%)					1 (2%)
Hepatocyte, Hyperplasia	1 (2%)					
Hepatocyte, Necrosis	5 (10%)	11 (23%)	4 (8%)	8 (17%)	10 (21%)	3 (6%)
Mesentery	(2)	(1)	(3)	(1)	(5)	(2)
Hemorrhage			1 (33%)			
Necrosis		1 (100%)	3 (100%)	1 (100%)	4 (80%)	2 (100%)
Pancreas	(48)	(48)	(48)	(47)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Infiltration Cellular, Lymphocyte	14 (29%)	4 (8%)	12 (25%)	7 (15%)	10 (21%)	8 (17%)
Infiltration Cellular, Polymorphonuclear						1 (2%)
Inflammation, Chronic Active			1 (2%)			
Necrosis						1 (2%)
Acinus, Degeneration	1 (2%)	1 (2%)	1 (2%)			
Artery, Degeneration		1 (2%)		1 (2%)		
Artery, Inflammation, Chronic Active		1 (2%)		1 (2%)		
Duct, Cyst	1 (2%)		1 (2%)			
Fat, Necrosis		1 (2%)			1 (2%)	
Salivary Glands	(48)	(48)	(48)	(48)	(48)	(48)
Infiltration Cellular, Lymphocyte	42 (88%)	41 (85%)	45 (94%)	40 (83%)	42 (88%)	37 (77%)
Infiltration Cellular, Polymorphonuclear						1 (2%)
Stomach, Forestomach	(48)	(48)	(48)	(47)	(48)	(48)
Infiltration Cellular, Lymphocyte	1 (2%)					
Inflammation, Suppurative	1 (2%)					
Inflammation, Chronic Active			2 (4%)			
Ulcer			1 (2%)			
Epithelium, Hyperplasia	2 (4%)	1 (2%)	3 (6%)	2 (4%)		
Stomach, Glandular	(48)	(48)	(46)	(46)	(48)	(48)
Cyst	4 (8%)	1 (2%)	1 (2%)	1 (2%)	3 (6%)	
Mineralization	1 (2%)	1 (2%)		1 (2%)		
Epithelium, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Tongue	(0)	(0)	(0)	(1)	(0)	(0)

CARDIOVASCULAR SYSTEM

Blood Vessel	(48)	(48)	(47)	(48)	(48)	(48)
Heart	(48)	(48)	(48)	(48)	(48)	(48)
Arteritis			1 (2%)		1 (2%)	
Bacterium	1 (2%)					
Cardiomyopathy	2 (4%)	2 (4%)	3 (6%)	1 (2%)	6 (13%)	2 (4%)
Infiltration Cellular, Lymphocyte			1 (2%)			
Inflammation, Chronic Active	1 (2%)	1 (2%)				
Mineralization					1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
ENDOCRINE SYSTEM						
Adrenal Cortex	(47)	(48)	(48)	(47)	(47)	(48)
Accessory Adrenal Cortical Nodule	2 (4%)		2 (4%)	2 (4%)	2 (4%)	1 (2%)
Amyloid Deposition	4 (9%)	2 (4%)	2 (4%)	1 (2%)	3 (6%)	3 (6%)
Cyst				1 (2%)	1 (2%)	
Hyperplasia			1 (2%)			
Hypertrophy	2 (4%)	1 (2%)	3 (6%)	4 (9%)	2 (4%)	2 (4%)
Vacuolization Cytoplasmic					1 (2%)	
Subcapsular, Hyperplasia	43 (91%)	41 (85%)	46 (96%)	44 (94%)	37 (79%)	44 (92%)
Adrenal Medulla	(47)	(47)	(48)	(47)	(46)	(48)
Hyperplasia				1 (2%)		
Islets, Pancreatic	(48)	(48)	(48)	(47)	(48)	(47)
Hyperplasia	6 (13%)	5 (10%)	3 (6%)	7 (15%)	7 (15%)	4 (9%)
Parathyroid Gland	(41)	(46)	(46)	(44)	(44)	(45)
Cyst	2 (5%)	3 (7%)		1 (2%)	1 (2%)	3 (7%)
Ectopic Thymus				1 (2%)		
Pituitary Gland	(48)	(46)	(46)	(47)	(46)	(45)
Pars Distalis, Cyst	1 (2%)	3 (7%)	2 (4%)	2 (4%)	1 (2%)	3 (7%)
Pars Distalis, Hyperplasia			1 (2%)	1 (2%)	1 (2%)	2 (4%)
Pars Distalis, Hypertrophy			1 (2%)			
Thyroid Gland	(48)	(48)	(48)	(47)	(48)	(47)
Infiltration Cellular, Lymphocyte					1 (2%)	1 (2%)
C-cell, Hyperplasia	2 (4%)	1 (2%)	2 (4%)	3 (6%)		1 (2%)
Follicle, Cyst	1 (2%)	3 (6%)	2 (4%)	3 (6%)	2 (4%)	1 (2%)
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(2)	(0)
Infiltration Cellular, Lymphocyte					1 (50%)	
Mineralization					1 (50%)	
Necrosis					1 (50%)	
Pigmentation					1 (50%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
GENITAL SYSTEM						
Epididymis	(48)	(48)	(48)	(48)	(48)	(48)
Exfoliated Germ Cell	3 (6%)		2 (4%)	1 (2%)	1 (2%)	
Fibrosis	1 (2%)			1 (2%)		
Granuloma Sperm	1 (2%)					
Hypospermia	2 (4%)		2 (4%)	4 (8%)	1 (2%)	
Infiltration Cellular, Lymphocyte	6 (13%)	6 (13%)	3 (6%)	9 (19%)	6 (13%)	5 (10%)
Spermatocoele		1 (2%)	1 (2%)	1 (2%)		1 (2%)
Adventitia, Inflammation, Chronic Active				1 (2%)		
Epithelium, Hyperplasia	1 (2%)					
Fat Pad, Epididymal	(0)	(0)	(0)	(1)	(1)	(0)
Fibrosis				1 (100%)		
Inflammation, Chronic Active				1 (100%)		
Mineralization				1 (100%)		
Necrosis				1 (100%)		
Preputial Gland	(48)	(48)	(48)	(48)	(48)	(48)
Abscess	2 (4%)	2 (4%)	4 (8%)	1 (2%)	2 (4%)	3 (6%)
Atrophy			1 (2%)		1 (2%)	
Fibrosis		1 (2%)				
Hyperkeratosis						1 (2%)
Infiltration Cellular, Lymphocyte	32 (67%)	25 (52%)	21 (44%)	29 (60%)	26 (54%)	23 (48%)
Infiltration Cellular, Plasma Cell	2 (4%)	1 (2%)	1 (2%)			2 (4%)
Inflammation, Suppurative	2 (4%)	8 (17%)	3 (6%)	2 (4%)	3 (6%)	4 (8%)
Inflammation, Chronic					1 (2%)	
Inflammation, Chronic Active			1 (2%)			
Duct, Dilatation	44 (92%)	44 (92%)	47 (98%)	48 (100%)	46 (96%)	47 (98%)
Epithelium, Hyperplasia		2 (4%)		1 (2%)		
Prostate	(48)	(48)	(48)	(47)	(48)	(48)
Infiltration Cellular, Lymphocyte	22 (46%)	18 (38%)	20 (42%)	20 (43%)	22 (46%)	26 (54%)
Seminal Vesicle	(48)	(48)	(46)	(46)	(48)	(48)
Fibrosis			1 (2%)			
Infiltration Cellular, Lymphocyte				1 (2%)		
Inflammation, Chronic			1 (2%)			
Inflammation, Chronic Active						1 (2%)
Lumen, Dilatation	7 (15%)	6 (13%)	4 (9%)	8 (17%)	4 (8%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Testes	(48)	(48)	(47)	(48)	(48)	(48)
Infiltration Cellular, Lymphocyte					1 (2%)	
Spermatocoele			1 (2%)			
Interstitial Cell, Hyperplasia					1 (2%)	
Seminiferous Tubule, Degeneration	4 (8%)	2 (4%)	5 (11%)	5 (10%)	2 (4%)	
Seminiferous Tubule, Dilatation						2 (4%)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(48)	(48)	(47)	(48)	(48)
Erythroid Cell, Hyperplasia		1 (2%)	1 (2%)			
Myeloid Cell, Hyperplasia	7 (15%)	7 (15%)	4 (8%)	4 (9%)	8 (17%)	8 (17%)
Lymph Node	(2)	(3)	(4)	(3)	(2)	(2)
Axillary, Hyperplasia, Lymphoid			1 (25%)			
Axillary, Infiltration Cellular, Plasma Cell		1 (33%)				
Inguinal, Hyperplasia, Lymphoid			1 (25%)			
Lumbar, Hyperplasia, Lymphoid				1 (33%)		
Lumbar, Infiltration Cellular, Histiocyte				1 (33%)		
Mediastinal, Hyperplasia, Lymphoid				1 (33%)		
Pancreatic, Hyperplasia, Lymphoid		1 (33%)				
Renal, Hyperplasia, Lymphoid		1 (33%)		1 (33%)		
Renal, Infiltration Cellular, Polymorphonuclear						1 (50%)
Lymph Node, Mandibular	(47)	(46)	(48)	(48)	(48)	(47)
Hyperplasia, Lymphoid	7 (15%)	12 (26%)	11 (23%)	14 (29%)	17 (35%)	15 (32%)
Infiltration Cellular, Lymphocyte					1 (2%)	
Infiltration Cellular, Plasma Cell		2 (4%)				
Pigmentation				1 (2%)		
Lymph Node, Mesenteric	(48)	(48)	(47)	(47)	(48)	(47)
Angiectasis	2 (4%)			2 (4%)	3 (6%)	
Degeneration, Cystic	1 (2%)			1 (2%)		
Fibrosis				1 (2%)		
Foreign Body				1 (2%)		
Hematopoietic Cell Proliferation	1 (2%)				1 (2%)	
Hemorrhage	6 (13%)	5 (10%)	7 (15%)	4 (9%)	5 (10%)	6 (13%)
Histiocytosis						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Hyperplasia, Lymphoid	30 (63%)	35 (73%)	35 (74%)	24 (51%)	35 (73%)	35 (74%)
Infiltration Cellular, Histiocyte	8 (17%)	7 (15%)	5 (11%)	5 (11%)	10 (21%)	6 (13%)
Infiltration Cellular, Mast Cell				1 (2%)		1 (2%)
Infiltration Cellular, Plasma Cell	4 (8%)	5 (10%)	2 (4%)	4 (9%)	2 (4%)	4 (9%)
Infiltration Cellular, Polymorphonuclear		1 (2%)				1 (2%)
Inflammation, Chronic Active				1 (2%)		
Pigmentation				1 (2%)		
Spleen	(47)	(48)	(48)	(47)	(48)	(48)
Angiectasis	1 (2%)					
Hematopoietic Cell Proliferation	22 (47%)	26 (54%)	21 (44%)	25 (53%)	20 (42%)	29 (60%)
Hyperplasia, Lymphoid	39 (83%)	41 (85%)	38 (79%)	39 (83%)	39 (81%)	35 (73%)
Inflammation, Granulomatous			1 (2%)			
Necrosis			1 (2%)			
Thymus	(46)	(44)	(46)	(43)	(44)	(48)
Atrophy	45 (98%)	43 (98%)	46 (100%)	42 (98%)	43 (98%)	47 (98%)
Cyst	1 (2%)			1 (2%)		1 (2%)
Hemorrhage			1 (2%)			
INTEGUMENTARY SYSTEM						
Mammary Gland	(1)	(2)	(0)	(2)	(2)	(0)
Skin	(48)	(48)	(48)	(48)	(48)	(48)
Cyst Epithelial Inclusion				1 (2%)	1 (2%)	
Necrosis		1 (2%)			1 (2%)	
Dermis, Inflammation, Chronic Active	1 (2%)	1 (2%)				
Epidermis, Hyperplasia	1 (2%)	3 (6%)				1 (2%)
Epidermis, Inflammation, Suppurative	1 (2%)	1 (2%)				1 (2%)
Epidermis, Ulcer	1 (2%)	2 (4%)				1 (2%)
Subcutaneous Tissue, Inflammation, Chronic Active		1 (2%)				
Skin, Control	(48)	(48)	(48)	(48)	(48)	(48)
Infiltration Cellular, Mast Cell			1 (2%)			
Dermis, Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)		
Epidermis, Hyperplasia	1 (2%)	1 (2%)	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Epidermis, Inflammation, Suppurative	1 (2%)	1 (2%)	2 (4%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Epidermis, Ulcer	1 (2%)	1 (2%)	1 (2%)	1 (2%)		
Skin, Site Of Application	(48)	(48)	(48)	(48)	(48)	(48)
Infiltration Cellular, Mast Cell						1 (2%)
Dermis, Fibrosis				1 (2%)		
Dermis, Inflammation, Chronic Active		1 (2%)	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Epidermis, Hyperplasia	1 (2%)	3 (6%)	20 (42%)	2 (4%)	17 (35%)	43 (90%)
Epidermis, Inflammation, Suppurative		3 (6%)	2 (4%)	2 (4%)	4 (8%)	9 (19%)
Epidermis, Necrosis		1 (2%)				
Epidermis, Ulcer		2 (4%)	1 (2%)	2 (4%)	2 (4%)	5 (10%)
MUSCULOSKELETAL SYSTEM						
Bone	(0)	(1)	(1)	(0)	(3)	(0)
Cranium, Hyperostosis			1 (100%)		2 (67%)	
Bone, Femur	(48)	(48)	(48)	(48)	(48)	(48)
Fibro-Osseous Lesion		1 (2%)	3 (6%)	1 (2%)		
Skeletal Muscle	(0)	(2)	(1)	(0)	(4)	(0)
Regeneration					1 (25%)	
NERVOUS SYSTEM						
Brain, Brain Stem	(48)	(48)	(48)	(48)	(48)	(48)
Hemorrhage	1 (2%)					
Brain, Cerebellum	(48)	(48)	(48)	(48)	(48)	(48)
Hemorrhage	1 (2%)					
Brain, Cerebrum	(48)	(48)	(48)	(48)	(48)	(48)
Hemorrhage	1 (2%)					
Infiltration Cellular, Lymphocyte			1 (2%)			
Mineralization	27 (56%)	28 (58%)	32 (67%)	25 (52%)	39 (81%)	27 (56%)
Nerve Trigeminal	(0)	(1)	(1)	(0)	(0)	(0)
Peripheral Nerve, Sciatic	(0)	(1)	(1)	(0)	(0)	(0)
Axon, Degeneration		1 (100%)				
Spinal Cord, Cervical	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Lumbar	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Thoracic	(0)	(1)	(1)	(0)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Demyelination			1 (100%)			
RESPIRATORY SYSTEM						
Lung	(48)	(48)	(48)	(48)	(48)	(48)
Hemorrhage	3 (6%)	1 (2%)	2 (4%)	2 (4%)		
Infiltration Cellular, Histiocyte	3 (6%)	5 (10%)	1 (2%)	5 (10%)	3 (6%)	9 (19%)
Infiltration Cellular, Polymorphonuclear						1 (2%)
Inflammation, Chronic Active						1 (2%)
Metaplasia, Osseous		1 (2%)				
Mineralization		1 (2%)				
Pigmentation						1 (2%)
Alveolar Epithelium, Hyperplasia	4 (8%)	3 (6%)	2 (4%)	1 (2%)	5 (10%)	2 (4%)
Nose	(48)	(48)	(48)	(48)	(48)	(48)
Eosinophilic Material	47 (98%)	48 (100%)	48 (100%)	47 (98%)	48 (100%)	48 (100%)
Hemorrhage	1 (2%)					
Inflammation, Suppurative				1 (2%)		
Inflammation, Chronic Active					1 (2%)	2 (4%)
Olfactory Epithelium, Accumulation, Hyaline Droplet				1 (2%)		
Posterior To Upper Incisor, Malformation	3 (6%)	1 (2%)	3 (6%)	7 (15%)	5 (10%)	1 (2%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	9 (19%)	8 (17%)	16 (33%)	8 (17%)	6 (13%)	11 (23%)
Trachea	(48)	(48)	(48)	(47)	(48)	(48)
SPECIAL SENSES SYSTEM						
Eye	(47)	(48)	(44)	(47)	(48)	(47)
Cataract	3 (6%)	2 (4%)	2 (5%)	2 (4%)	2 (4%)	3 (6%)
Phthisis Bulbi				2 (4%)		1 (2%)
Cornea, Edema	1 (2%)					
Harderian Gland	(48)	(48)	(48)	(47)	(48)	(48)
Infiltration Cellular, Lymphocyte	24 (50%)	15 (31%)	21 (44%)	26 (55%)	24 (50%)	18 (38%)
Infiltration Cellular, Polymorphonuclear						1 (2%)
Acinus, Degeneration				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(47)	(48)	(48)
Bacterium	1 (2%)					
Casts		1 (2%)				
Infarct	5 (10%)	7 (15%)	6 (13%)	4 (9%)	3 (6%)	4 (8%)
Infiltration Cellular, Lymphocyte	2 (4%)	4 (8%)	3 (6%)	4 (9%)	7 (15%)	6 (13%)
Infiltration Cellular, Polymorphonuclear						1 (2%)
Inflammation, Chronic Active				1 (2%)		
Metaplasia, Osseous	1 (2%)	1 (2%)	1 (2%)	1 (2%)		2 (4%)
Mineralization	3 (6%)	2 (4%)	3 (6%)	3 (6%)	2 (4%)	
Necrosis				1 (2%)		
Nephropathy	45 (94%)	45 (94%)	47 (98%)	43 (91%)	41 (85%)	43 (90%)
Cortex, Cyst	1 (2%)	1 (2%)	1 (2%)		1 (2%)	2 (4%)
Renal Tubule, Cyst	7 (15%)	10 (21%)	11 (23%)	8 (17%)	11 (23%)	3 (6%)
Urinary Bladder	(48)	(48)	(48)	(47)	(48)	(48)
Calculus Micro Observation Only	1 (2%)					
Infiltration Cellular, Lymphocyte	6 (13%)	5 (10%)	11 (23%)	9 (19%)	15 (31%)	8 (17%)
Lumen, Dilatation		1 (2%)	3 (6%)	1 (2%)	3 (6%)	
Transitional Epithelium, Hyperplasia	1 (2%)					

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	11	17	17	14	8	10
Natural Death	1	1			3	2
Survivors						
Moribund	1	1		1		1
Terminal Sacrifice	35	29	31	33	37	35
Animals Examined Microscopically	48	48	48	48	48	48

ALIMENTARY SYSTEM

Esophagus	(48)	(48)	(48)	(48)	(48)	(48)
Gallbladder	(45)	(46)	(44)	(47)	(45)	(44)
Fibrosis					1 (2%)	
Infiltration Cellular, Lymphocyte	1 (2%)	1 (2%)				3 (7%)
Inflammation, Chronic Active		1 (2%)				
Lumen, Dilatation					1 (2%)	
Intestine Large, Cecum	(47)	(48)	(48)	(48)	(45)	(46)
Inflammation, Chronic Active		1 (2%)				
Intestine Large, Colon	(47)	(47)	(48)	(48)	(45)	(46)
Inflammation, Chronic Active	1 (2%)	1 (2%)				
Intestine Large, Rectum	(47)	(48)	(48)	(48)	(45)	(46)
Inflammation, Suppurative			1 (2%)			
Ulcer			1 (2%)			
Intestine Small, Duodenum	(47)	(47)	(48)	(48)	(45)	(46)
Fibrosis				1 (2%)		
Inflammation, Suppurative			1 (2%)			
Inflammation, Chronic Active	1 (2%)			1 (2%)		1 (2%)
Necrosis			1 (2%)			
Ulcer			1 (2%)			1 (2%)
Intestine Small, Ileum	(47)	(48)	(48)	(48)	(45)	(46)
Infiltration Cellular, Plasma Cell						1 (2%)
Inflammation, Suppurative						1 (2%)
Inflammation, Chronic Active	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Ulcer						1 (2%)
Lymphoid Tissue, Hyperplasia	1 (2%)					
Intestine Small, Jejunum	(47)	(48)	(48)	(48)	(45)	(46)
Inflammation, Suppurative	1 (2%)			1 (2%)		
Necrosis				1 (2%)		
Perforation				1 (2%)		
Ulcer	1 (2%)			1 (2%)		
Lymphoid Tissue, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	1 (2%)		1 (2%)
Liver	(48)	(48)	(48)	(48)	(48)	(48)
Angiectasis	2 (4%)	1 (2%)	1 (2%)			
Arteritis				1 (2%)		
Basophilic Focus	3 (6%)	5 (10%)	3 (6%)	2 (4%)	2 (4%)	5 (10%)
Clear Cell Focus			1 (2%)	2 (4%)	1 (2%)	
Cyst			1 (2%)	1 (2%)	1 (2%)	
Deformity	1 (2%)	1 (2%)				
Eosinophilic Focus	1 (2%)					1 (2%)
Fatty Change						1 (2%)
Fibrosis			2 (4%)			
Hematopoietic Cell Proliferation	2 (4%)	1 (2%)		1 (2%)	1 (2%)	1 (2%)
Hypertrophy			1 (2%)			
Infiltration Cellular, Lymphocyte	21 (44%)	22 (46%)	17 (35%)	21 (44%)	19 (40%)	19 (40%)
Inflammation, Chronic			1 (2%)		1 (2%)	1 (2%)
Inflammation, Chronic Active	3 (6%)	5 (10%)	5 (10%)	4 (8%)	2 (4%)	2 (4%)
Mineralization				1 (2%)		
Mixed Cell Focus			1 (2%)			
Tension Lipidosis	2 (4%)	1 (2%)	2 (4%)	1 (2%)		1 (2%)
Thrombosis		1 (2%)	1 (2%)			
Vacuolization Cytoplasmic	4 (8%)	5 (10%)	2 (4%)		2 (4%)	1 (2%)
Bile Duct, Cyst						1 (2%)
Hepatocyte, Necrosis	2 (4%)	2 (4%)	6 (13%)	6 (13%)	5 (10%)	4 (8%)
Mesentery	(7)	(4)	(11)	(14)	(8)	(6)
Inflammation, Chronic Active					2 (25%)	
Mineralization					1 (13%)	
Necrosis	7 (100%)	4 (100%)	10 (91%)	14 (100%)	7 (88%)	6 (100%)
Fat, Infiltration Cellular, Lymphocyte					1 (13%)	
Pancreas	(48)	(48)	(48)	(48)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Fibrosis		1 (2%)		1 (2%)		
Histiocytosis		1 (2%)				
Infiltration Cellular, Lymphocyte	26 (54%)	25 (52%)	22 (46%)	31 (65%)	25 (52%)	22 (46%)
Inflammation, Suppurative		1 (2%)				
Inflammation, Chronic Active		1 (2%)	1 (2%)			
Mineralization		1 (2%)				
Necrosis		1 (2%)				
Thrombosis					1 (2%)	
Vacuolization Cytoplasmic			1 (2%)		1 (2%)	1 (2%)
Acinus, Degeneration			3 (6%)		1 (2%)	1 (2%)
Duct, Cyst			1 (2%)			
Duct, Dilatation			1 (2%)	1 (2%)		3 (6%)
Duct, Hemorrhage				1 (2%)		
Duct, Inflammation, Chronic Active				1 (2%)		
Duct, Ulcer				1 (2%)		
Fat, Necrosis	1 (2%)	1 (2%)		1 (2%)	1 (2%)	
Salivary Glands	(48)	(48)	(48)	(48)	(48)	(48)
Infiltration Cellular, Lymphocyte	36 (75%)	38 (79%)	39 (81%)	36 (75%)	39 (81%)	35 (73%)
Stomach, Forestomach	(48)	(48)	(48)	(48)	(48)	(48)
Fibrosis	1 (2%)					
Inflammation, Chronic Active	1 (2%)					
Keratin Cyst		1 (2%)		1 (2%)		
Epithelium, Hyperplasia	2 (4%)		2 (4%)		1 (2%)	
Stomach, Glandular	(47)	(48)	(48)	(48)	(45)	(46)
Cyst	4 (9%)	1 (2%)		4 (8%)	1 (2%)	
Fibrosis	1 (2%)					
Infiltration Cellular, Lymphocyte			1 (2%)			
Mineralization		1 (2%)		2 (4%)		
Ulcer						1 (2%)
Epithelium, Hyperplasia	2 (4%)	1 (2%)	1 (2%)		1 (2%)	1 (2%)
Tongue	(0)	(0)	(0)	(0)	(0)	(1)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(48)	(48)	(48)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Heart	(48)	(48)	(48)	(48)	(48)	(48)
Cardiomyopathy	2 (4%)	1 (2%)		2 (4%)	1 (2%)	2 (4%)
Inflammation, Chronic Active			1 (2%)			1 (2%)
Mineralization						1 (2%)
Polyarteritis		1 (2%)		1 (2%)		1 (2%)
Thrombosis						1 (2%)
Myocardium, Necrosis			1 (2%)			
ENDOCRINE SYSTEM						
Adrenal Cortex	(48)	(48)	(48)	(48)	(48)	(48)
Accessory Adrenal Cortical Nodule	3 (6%)	1 (2%)	3 (6%)	3 (6%)	2 (4%)	
Amyloid Deposition	44 (92%)	42 (88%)	43 (90%)	42 (88%)	39 (81%)	44 (92%)
Angiectasis	1 (2%)	1 (2%)	1 (2%)	1 (2%)		1 (2%)
Cyst	2 (4%)	1 (2%)		1 (2%)		
Hypertrophy		1 (2%)			1 (2%)	
Infiltration Cellular, Polymorphonuclear		1 (2%)				
Vacuolization Cytoplasmic	1 (2%)			1 (2%)	2 (4%)	2 (4%)
Subcapsular, Hyperplasia	47 (98%)	48 (100%)	47 (98%)	46 (96%)	47 (98%)	48 (100%)
Adrenal Medulla	(48)	(48)	(48)	(47)	(48)	(48)
Hyperplasia	1 (2%)		1 (2%)		1 (2%)	2 (4%)
Islets, Pancreatic	(48)	(48)	(48)	(48)	(48)	(48)
Angiectasis						1 (2%)
Hyperplasia	1 (2%)		1 (2%)			1 (2%)
Parathyroid Gland	(44)	(45)	(45)	(43)	(45)	(43)
Cyst		1 (2%)	2 (4%)	2 (5%)		2 (5%)
Ectopic Thymus	1 (2%)			1 (2%)		1 (2%)
Pituitary Gland	(47)	(47)	(47)	(47)	(46)	(46)
Angiectasis	1 (2%)	2 (4%)	3 (6%)	4 (9%)	2 (4%)	7 (15%)
Infiltration Cellular, Histiocyte				1 (2%)		
Necrosis				1 (2%)		
Pigmentation				1 (2%)		
Pars Distalis, Cyst				1 (2%)		2 (4%)
Pars Distalis, Hyperplasia	3 (6%)	4 (9%)	5 (11%)	6 (13%)	1 (2%)	9 (20%)
Pars Distalis, Hypertrophy		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Thyroid Gland	(48)	(48)	(48)	(48)	(48)	(48)
Ectopic Thymus					1 (2%)	
Infiltration Cellular, Lymphocyte	2 (4%)	4 (8%)		3 (6%)	1 (2%)	
C-cell, Hyperplasia	9 (19%)	4 (8%)	2 (4%)	8 (17%)	5 (10%)	2 (4%)
Follicle, Cyst	5 (10%)	3 (6%)	4 (8%)	6 (13%)	3 (6%)	7 (15%)
Follicular Cell, Hyperplasia				1 (2%)		
<hr/>						
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(3)	(2)	(1)	(0)	(1)
Hemorrhage						1 (100%)
Infiltration Cellular, Lymphocyte		1 (33%)				
Inflammation, Chronic Active				1 (100%)		
Mineralization				1 (100%)		
Necrosis		2 (67%)		1 (100%)		
<hr/>						
GENITAL SYSTEM						
Clitoral Gland	(46)	(44)	(45)	(45)	(45)	(43)
Duct, Dilatation	18 (39%)	26 (59%)	22 (49%)	22 (49%)	13 (29%)	15 (35%)
Fat Pad, Ovarian/parametrial	(0)	(0)	(1)	(0)	(0)	(0)
Necrosis			1 (100%)			
Ovary	(48)	(48)	(48)	(48)	(48)	(48)
Angiectasis				1 (2%)		
Atrophy	46 (96%)	46 (96%)	45 (94%)	47 (98%)	46 (96%)	46 (96%)
Cyst	9 (19%)	5 (10%)	7 (15%)	12 (25%)	10 (21%)	12 (25%)
Hematocyst	1 (2%)	1 (2%)		1 (2%)		2 (4%)
Hyperplasia, Tubulostromal		1 (2%)				
Infiltration Cellular, Lymphocyte					1 (2%)	
Inflammation, Suppurative	1 (2%)					
Mineralization				1 (2%)		
Pigmentation			1 (2%)			
Bilateral, Cyst			1 (2%)			1 (2%)
Epithelium, Hyperplasia			1 (2%)			
Uterus	(48)	(48)	(48)	(48)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Abscess		1 (2%)				
Infiltration Cellular, Polymorphonuclear Inflammation, Chronic			1 (2%)	1 (2%)	2 (4%)	2 (4%)
Inflammation, Chronic Active			1 (2%)			1 (2%)
Mineralization	1 (2%)					
Necrosis		1 (2%)			1 (2%)	
Pigmentation	1 (2%)					1 (2%)
Thrombosis					1 (2%)	1 (2%)
Endometrium, Hyperplasia, Cystic Lumen, Dilatation	48 (100%) 2 (4%)	47 (98%)	48 (100%)	48 (100%) 2 (4%)	46 (96%) 1 (2%)	48 (100%) 1 (2%)
Muscularis, Degeneration			1 (2%)			

HEMATOPOIETIC SYSTEM

Bone Marrow	(47)	(48)	(48)	(48)	(48)	(48)
Erythroid Cell, Hyperplasia		1 (2%)				
Myeloid Cell, Hyperplasia	1 (2%)	3 (6%)	4 (8%)	3 (6%)	5 (10%)	2 (4%)
Lymph Node	(7)	(4)	(8)	(6)	(2)	(6)
Degeneration, Cystic				1 (17%)	1 (50%)	
Lumbar, Histiocytosis		1 (25%)				
Lumbar, Hyperplasia, Lymphoid					1 (50%)	1 (17%)
Lumbar, Infiltration Cellular, Plasma Cell		1 (25%)				
Lumbar, Inflammation, Chronic Active		1 (25%)				
Mediastinal, Hyperplasia, Lymphoid	2 (29%)					
Mediastinal, Infiltration Cellular, Plasma Cell	1 (14%)					
Renal, Hyperplasia, Lymphoid	1 (14%)			1 (17%)		1 (17%)
Lymph Node, Mandibular	(47)	(48)	(48)	(48)	(48)	(47)
Hyperplasia, Lymphoid	19 (40%)	14 (29%)	15 (31%)	16 (33%)	17 (35%)	15 (32%)
Infiltration Cellular, Histiocyte	1 (2%)	1 (2%)				
Infiltration Cellular, Lymphocyte	1 (2%)					
Infiltration Cellular, Plasma Cell	2 (4%)		2 (4%)			
Lymph Node, Mesenteric	(48)	(47)	(46)	(48)	(46)	(48)
Angiectasis					1 (2%)	1 (2%)
Foreign Body			1 (2%)			
Hemorrhage			2 (4%)			1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Hyperplasia, Lymphoid	27 (56%)	28 (60%)	29 (63%)	23 (48%)	23 (50%)	24 (50%)
Infiltration Cellular, Histiocyte	2 (4%)	1 (2%)	1 (2%)		2 (4%)	
Infiltration Cellular, Plasma Cell	1 (2%)	3 (6%)	3 (7%)		2 (4%)	
Infiltration Cellular, Polymorphonuclear				1 (2%)		
Inflammation, Chronic Active			1 (2%)			
Necrosis			1 (2%)			
Spleen	(48)	(48)	(48)	(48)	(48)	(48)
Amyloid Deposition		1 (2%)				
Angiectasis	1 (2%)			1 (2%)		
Hematopoietic Cell Proliferation	24 (50%)	30 (63%)	26 (54%)	27 (56%)	28 (58%)	23 (48%)
Hemorrhage			1 (2%)			
Hyperplasia, Lymphoid	36 (75%)	38 (79%)	34 (71%)	39 (81%)	39 (81%)	37 (77%)
Necrosis			2 (4%)			
Capsule, Inflammation, Chronic Active		1 (2%)				
Thymus	(47)	(46)	(48)	(48)	(48)	(48)
Atrophy	44 (94%)	42 (91%)	42 (88%)	42 (88%)	47 (98%)	44 (92%)
Hyperplasia, Lymphoid	1 (2%)	1 (2%)		2 (4%)		2 (4%)
Epithelium, Hyperplasia				1 (2%)		

INTEGUMENTARY SYSTEM

Mammary Gland	(47)	(48)	(46)	(46)	(47)	(47)
Alveolus, Hyperplasia			1 (2%)		1 (2%)	1 (2%)
Skin	(48)	(48)	(48)	(48)	(48)	(48)
Cyst Epithelial Inclusion		1 (2%)				
Dermis, Inflammation, Chronic Active	1 (2%)					
Epidermis, Hyperplasia		1 (2%)		1 (2%)	2 (4%)	1 (2%)
Epidermis, Inflammation, Suppurative	1 (2%)					
Epidermis, Ulcer	1 (2%)					
Sebaceous Gland, Hyperplasia					1 (2%)	
Subcutaneous Tissue, Edema	1 (2%)					
Subcutaneous Tissue, Inflammation, Chronic	1 (2%)					
Skin, Control	(48)	(48)	(48)	(48)	(48)	(48)
Epidermis, Hyperplasia		1 (2%)	1 (2%)			2 (4%)
Skin, Site Of Application	(48)	(48)	(48)	(48)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Infiltration Cellular, Mast Cell Dermis, Fibrosis		1 (2%)				1 (2%)
Dermis, Inflammation, Chronic Active		2 (4%)				1 (2%)
Epidermis, Hyperplasia		5 (10%)	7 (15%)	1 (2%)	10 (21%)	39 (81%)
Epidermis, Inflammation, Suppurative		3 (6%)	1 (2%)		2 (4%)	4 (8%)
Epidermis, Ulcer		2 (4%)			1 (2%)	

MUSCULOSKELETAL SYSTEM

Bone	(0)	(1)	(0)	(0)	(1)	(0)
Bone, Femur	(48)	(48)	(48)	(48)	(48)	(48)
Fibro-Osseous Lesion	13 (27%)	10 (21%)	8 (17%)	7 (15%)	11 (23%)	10 (21%)
Skeletal Muscle	(1)	(2)	(2)	(3)	(0)	(0)

NERVOUS SYSTEM

Brain, Brain Stem	(48)	(48)	(48)	(48)	(48)	(48)
Compression		1 (2%)	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Brain, Cerebellum	(48)	(48)	(48)	(48)	(48)	(48)
Compression					1 (2%)	
Brain, Cerebrum	(48)	(48)	(48)	(48)	(48)	(48)
Metaplasia, Osseous Mineralization	30 (63%)	29 (60%)	27 (56%)	31 (65%)	25 (52%)	33 (69%)
Ventricle, Dilatation		1 (2%)	1 (2%)		1 (2%)	
Nerve Trigeminal	(0)	(0)	(1)	(1)	(0)	(0)
Peripheral Nerve, Sciatic	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord	(0)	(0)	(0)	(1)	(0)	(0)
Spinal Cord, Cervical	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord, Lumbar	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord, Thoracic	(0)	(0)	(1)	(1)	(0)	(0)

RESPIRATORY SYSTEM

Lung	(48)	(48)	(48)	(48)	(48)	(48)
------	------	------	------	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Hemorrhage	1 (2%)			1 (2%)		
Histiocytosis		1 (2%)				
Infiltration Cellular, Histiocyte	2 (4%)	2 (4%)	3 (6%)	5 (10%)	3 (6%)	3 (6%)
Infiltration Cellular, Lymphocyte		3 (6%)			1 (2%)	
Mineralization	1 (2%)					
Necrosis				1 (2%)		
Pigmentation				1 (2%)		
Alveolar Epithelium, Hyperplasia	2 (4%)		3 (6%)	2 (4%)	2 (4%)	3 (6%)
Nose	(48)	(48)	(48)	(48)	(48)	(48)
Eosinophilic Material	44 (92%)	42 (88%)	44 (92%)	43 (90%)	46 (96%)	42 (88%)
Inflammation, Chronic		1 (2%)				
Olfactory Epithelium, Accumulation, Hyaline Droplet	2 (4%)	1 (2%)	2 (4%)	3 (6%)	4 (8%)	1 (2%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	34 (71%)	34 (71%)	27 (56%)	33 (69%)	34 (71%)	30 (63%)
Trachea	(48)	(48)	(48)	(48)	(48)	(48)
SPECIAL SENSES SYSTEM						
Eye	(47)	(46)	(48)	(48)	(45)	(46)
Cataract	2 (4%)	4 (9%)	2 (4%)	1 (2%)	2 (4%)	2 (4%)
Phthisis Bulbi	1 (2%)	1 (2%)		1 (2%)	1 (2%)	
Bilateral, Cataract	1 (2%)					
Harderian Gland	(48)	(48)	(47)	(48)	(48)	(47)
Infiltration Cellular, Lymphocyte	18 (38%)	25 (52%)	25 (53%)	27 (56%)	24 (50%)	27 (57%)
Zymbal's Gland	(0)	(1)	(1)	(0)	(0)	(0)
Cyst, Squamous			1 (100%)			
Inflammation, Suppurative		1 (100%)	1 (100%)			
Duct, Dilatation		1 (100%)				
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(48)	(48)	(48)
Accumulation, Hyaline Droplet			2 (4%)		1 (2%)	1 (2%)
Casts		2 (4%)	1 (2%)			1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlIFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Infarct	7 (15%)	6 (13%)	9 (19%)	7 (15%)	5 (10%)	8 (17%)
Infiltration Cellular, Lymphocyte	29 (60%)	33 (69%)	33 (69%)	29 (60%)	31 (65%)	30 (63%)
Infiltration Cellular, Polymorphonuclear			1 (2%)			2 (4%)
Inflammation, Chronic Active					1 (2%)	
Metaplasia, Osseous	1 (2%)	1 (2%)	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Mineralization						1 (2%)
Nephropathy	14 (29%)	13 (27%)	10 (21%)	13 (27%)	11 (23%)	10 (21%)
Capsule, Fibrosis					1 (2%)	
Cortex, Cyst	1 (2%)		1 (2%)		1 (2%)	
Epithelium, Degeneration		1 (2%)				
Glomerulus, Amyloid Deposition		1 (2%)				
Pelvis, Dilatation		1 (2%)				
Renal Tubule, Cyst		1 (2%)	1 (2%)	2 (4%)		
Renal Tubule, Dilatation		1 (2%)				
Renal Tubule, Hyperplasia		2 (4%)	2 (4%)	1 (2%)		
Renal Tubule, Necrosis			1 (2%)		1 (2%)	
Urinary Bladder	(48)	(48)	(48)	(48)	(48)	(47)
Infiltration Cellular, Lymphocyte	24 (50%)	30 (63%)	25 (52%)	26 (54%)	22 (46%)	26 (55%)
Inflammation, Chronic Active		1 (2%)				1 (2%)
Lumen, Dilatation		1 (2%)				
Transitional Epithelium, Hyperplasia		1 (2%)	1 (2%)			1 (2%)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion